The microcap sell side stock research universe is fraught with misaligned incentives. Take, for example, shares of Sensus Healthcare (NASDAQ:SRTS), a small medical device manufacturer currently serving the dermatology and radiation oncology markets with its line of superficial radiation equipment (“SRT”).
Readers are directed to my Top Idea article for background information on the SRTS opportunity here. The basis for an attractive risk/reward for shares of SRTS includes the following:
- Potential revenue acceleration based on certain channel checks
- Potential inflection to GAAP profits assuming $8M+ Q4 revenue
- Q4 and FY 2019 Street